✓ No active regulatory warningsFDA MedWatch, EMA EudraVigilance, WHO VigiBase, WADA Prohibited List · 2026-05-29
📰Read the full PEA (Palmitoylethanolamide) evidence review on GMJ News →Complete clinical article, references and updates on news.gmj.ge. This page is the structured safety summary.⚠ Patient buying cheap native/crystalline PEA — poor bioavailability; insist on micronized or ultra-micronized [1]
⚠ Patient expecting immediate pain relief — needs 2–4 weeks loading; set expectations [2]
⚠ Patient confusing PEA with CBD or cannabis — entirely different molecule and mechanism [1]
⚠ Patient who could reduce NSAID dose — PEA as add-on may allow NSAID dose reduction (gastroprotective benefit) [1]
🥗 Food first — build your daily Typical 300–600 mg
Check the foods you regularly eat — the bar fills toward your daily target.
Egg yolk (1 large)2 mg PEA (approximate)
Soybean lecithin (10 g)3 mg PEA (approximate)
Peanuts (100 g)4 mg PEA (approximate)
Milk fat (100 g)1 mg PEA (approximate)
Check your regular foods above
🔬 Lab interpreter
Recommended test
No routine monitoring required
No routine monitoring required
Reference range / target
N/A
N/A
When to test
N/A
N/A
PEA has no known hepatic, renal, or hematological effects requiring monitoring [1].
Full lab monitoring ↓⚕ For professionals — confirm ranges against your local laboratory.
Clinical verdict
PEA is a legitimate analgesic nutraceutical with meta-analytic support (12 RCTs, n=1,188). The critical clinical point: form matters enormously. Ultra-micronized (um-PEA) has proven bioavailability; native crystalline PEA is poorly absorbed. Load at 600 mg BID × 4–6 weeks, then maintain at 300 mg BID. Excellent safety profile. Not a cannabinoid — no CB1/CB2 binding, no psychoactivity, no regulatory restrictions [1] [2].
1 How much do I need?
👤 Adults: Specific dosage data under clinical review
👴 Elderly: Specific dosage data under clinical review
🤰 Pregnancy: See guidance
Insufficient data. PEA is endogenous and theoretically low-risk but no pregnancy studies. Avoid supplementation [1].
👦 Pediatric: See guidance
Limited data. PEA has been studied in a few open-label pediatric trials for neurological conditions. No established pediatric dosing [1].
🏃 Athletes: Standard dose
⚖️ Obesity: Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
🩺 Renal: Consult specialist
Dose adjustment may be needed in renal impairment.
🌱 Vegan: Standard dose
How to take
🍽 Timing: Twice daily (BID). Morning and evening with meals [1].
💊 With food: Take with food (fat-containing) to improve absorption of this lipid-based molecule [1].
🚫 Avoid: Native/non-micronized PEA. Stopping too early (give 4–6 weeks). Sublingual PEA products (no bioavailability advantage proven) [1].
2 Which form?
| Form | Bioavailability | Vegan | Cost |
|---|---|---|---|
| ['Ultra-micronized PEA (um-PEA)', 'preferred', 'Particle size <6 µm. Superior absorption vs native PEA crystals. Most clinical evidence uses this form (Normast®, PeaPure®) [1].'] | Standard | Check label | |
| ['Micronized PEA (m-PEA)', 'acceptable', 'Particle size 2–10 µm. Better than native, slightly less bioavailable than ultra-micronized [1].'] | Standard | Check label | |
| ['Native PEA (crystalline)', 'inferior', 'Poor bioavailability due to large crystal size. Not recommended despite lower cost [1].', 'orange'] | Standard | Check label | |
| ['PEA + Luteolin combination', 'clinical', 'Some products combine PEA with the flavonoid luteolin for neuroinflammatory conditions. Theoretical synergy through complementary anti-inflammatory pathways [1].'] | Standard | Check label |
3 Common questions
Is PEA the same as CBD? ▼
No. PEA and CBD are entirely different molecules with different mechanisms. PEA is an endogenous fatty acid amide that activates PPAR-α. CBD is a phytocannabinoid from cannabis that modulates endocannabinoid signaling and other targets. PEA is legal everywhere, not psychoactive, and has no regulatory restrictions [1].
Why does the form (micronized vs native) matter so much? ▼
Native PEA forms large crystals that are poorly absorbed in the gut. Micronization (m-PEA) and ultra-micronization (um-PEA) reduce particle size to <10 µm and <6 µm respectively, dramatically increasing surface area and bioavailability. Most clinical trials showing efficacy used um-PEA. Buying native crystalline PEA to save money may result in ineffective dosing [1].
How long does PEA take to work? ▼
Can PEA be combined with painkillers? ▼
Yes. PEA has been studied as an add-on to standard analgesics (paracetamol, NSAIDs, pregabalin) with improved outcomes and no adverse interactions. It may allow dose reduction of conventional analgesics, which is a clinical advantage [1].
4 Clinical evidence
Strong
Chronic pain (meta-analysis): a systematic review and meta-analysis of 12 RCTs (n=1,188) found um-PEA significantly reduced pain intensity across neuropathic pain, sciatica, carpal tunnel syndrome, and chronic pelvic pain compared with placebo (SMD −0.99, 95% CI −1.40 to −0.59) [2]. HIGH
Moderate
Sciatic pain: 600 mg um-PEA BID added to standard therapy improved pain scores more than standard therapy alone in 2 RCTs [1]. Carpal tunnel syndrome: um-PEA 600 mg BID for 30 days improved nerve conduction velocity and pain in 1 RCT (n=80) [1]. Endometriosis pain: 400 mg PEA + transpolydatin improved pain scores in 1 RCT vs placebo [1]. MODERATE
Insufficient
Depression/anxiety: PPAR-α and endocannabinoid modulation are relevant pathways, but no published RCTs for mood disorders [1]. Multiple sclerosis: open-label data only [1]. Fibromyalgia: 1 small open-label study; no RCTs [1]. COVID-19 inflammation: theoretical basis from mast cell modulation; no clinical trial data [1]. LOW
5 Safety, toxicity & adverse events
Relative
⚠ Generally very well tolerated; limited interaction data
⚠ Pregnancy and lactation — limited data
🚩 Red flags
● Patient using native crystalline PEA and reporting no benefit — likely a bioavailability problem [1]
● Patient replacing prescribed analgesics with PEA without medical guidance — PEA is adjunctive [1]
● Clinician unfamiliar with PEA dismissing it as 'unproven' — meta-analytic evidence exists [2]
6 Interactions
Drug interactions
NSAIDs (ibuprofen, naproxen) Low (beneficial)
Mechanism: PEA provides complementary anti-inflammatory pathways (PPAR-α vs COX) [1].
Effect: Additive pain relief; potential to reduce NSAID dose and GI risk [1].
Action: Combination may be clinically advantageous; monitor NSAID dose [1].
Gabapentinoids (pregabalin, gabapentin) Low (beneficial)
Mechanism: Different analgesic mechanisms; additive pain relief in neuropathic pain [1].
Effect: Improved pain outcomes in open-label add-on studies [1].
Action: Reasonable combination for neuropathic pain management [1].
Supplement synergies
Luteolin · 600 mg um-PEA + 70 mg luteolin
PEA + luteolin combination targets neuroinflammation through complementary pathways [1].
PEA + luteolin combination targets neuroinflammation through complementary pathways [1].
Alpha-Lipoic Acid · 600 mg ALA + 600 mg um-PEA
Both target neuropathic pain; different mechanisms (ALA: antioxidant/nerve regeneration; PEA: anti-inflammatory) [1].
Both target neuropathic pain; different mechanisms (ALA: antioxidant/nerve regeneration; PEA: anti-inflammatory) [1].
7 Regulatory
United States (FDA): Available as dietary supplement (classified as a food component/nutraceutical). No FDA-approved drug claims. Not a controlled substance [1].
European Union: Available as a food supplement in most EU countries. Marketed as Normast® (medical food) in Italy and Spain. Not classified as a drug in most jurisdictions [1].
Italy: Most extensively studied and prescribed. Normast® is classified as a 'food for special medical purposes.' Italian pain specialists commonly prescribe PEA [1].
Australia (TGA): Available as listed complementary medicine [1].
8 Cite this page
Vancouver: Pkhakadze G. PEA (Palmitoylethanolamide) — safety profile [Internet]. Tbilisi: PHIG; 2026 [cited 2026 Aug 15]. Available from: https://supplement.ge/ingredients/pea-palmitoylethanolamide/
APA 7th: Pkhakadze, G. (2026). PEA (Palmitoylethanolamide) — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/pea-palmitoylethanolamide/
📋 Editorial information
Author: Prof. G. Pkhakadze, MD, MPH, PhD
Institution: Public Health Institute of Georgia (PHIG)
Affiliation: David Tvildiani Medical University (DTMU)
First published: January 2026
Last reviewed: 2026-05-29
Next review: February 2027
References: 4 cited sources
COI: SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
Process: Systematic literature review
📄 License & reuse
Published under Creative Commons Attribution 4.0 International (CC BY 4.0). You may share and adapt for any purpose with attribution.
Pkhakadze G. "PEA (Palmitoylethanolamide) — Safety Profile." SupplementIndex, PHIG, 2026. https://supplement.ge/ingredients/pea-palmitoylethanolamide/ CC BY 4.0.
GP
Prof. G. Pkhakadze, MD, MPH, PhD
Professor of Public Health · Head of Department, DTMU
Editor-in-Chief, Georgian Medical Journal (ISSN 3088-4322)
Chair, Public Health Institute of Georgia · UEMS Public Health Section
Educational and public health purposes. CC BY 4.0. Consult your healthcare provider before starting any supplement. Corrections: info@accreditation.ge. Publisher: PHIG